SineuGene
Latest round
- Series A
Last raised
- Mar 2023
Total raised
- Undisclosed
Investors
- 3
About SineuGene
Established in 2021 and based in Beijing, China, SineuGene operates as a neural evaluation system developer that focuses on gene therapy for nervous system diseases. The co-founder and Chairman of the Scientific Advisory Board, Hechang Jia, is the Dean's Appointed Professor of Medicine at Tsinghua University. The CEO, Peng Lin, was the General Manager of Nanjing Tianyin Health Development. The company develops gene therapy drugs for neurological diseases, establishes a platform for novel knock-in animal disease models such as Drosophila, mice, and parmesan pigs, and develops therapeutic approaches targeting neurological diseases such as amyotrophic lateral sclerosis, stroke, and Parkinson's disease., which have entered the clinical trial stage and obtained ALS indications. The company generates revenue by developing therapeutic drugs for neurological disorders such as amyotrophic lateral sclerosis, stroke, and Parkinson's disease.
Who invested in SineuGene
3 investors across 1 round
See all investors in SineuGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 31, 2023
Amount
Undisclosed
Investors
Questions about SineuGene
Who invested in SineuGene?
SineuGene has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has SineuGene raised?
SineuGene has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did SineuGene last raise money?
SineuGene's most recent round on record is a Series A, in Mar 2023.
What does SineuGene do?
Established in 2021 and based in Beijing, China, SineuGene operates as a neural evaluation system developer that focuses on gene therapy for nervous system diseases.
Where is SineuGene headquartered?
SineuGene is headquartered in Beijing, China.
Which VCs invest in companies like SineuGene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at SineuGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like SineuGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.